VFEND

Invasive aspergillosis; candidaemia in non-neutropenic patients; fluconazole-resistant serious invasive Candida infections (including C. krusei); serious fungal infections caused by Scedosporium spp & Fusarium spp. Prophylaxis in patients who are at high risk of developing invasive fungal infections eg, allogeneic haematopoietic stem cell transplant (HSCT) recipients.

Adult Oral Loading dose (1st 24 hr): Patient ≥40 kg 400 mg 12 hrly, <40 kg 200 mg 12 hrly. Maintenance dose (after 1st 24 hr): Prophylaxis of invasive fungal infections, serious invasive Candida/invasive aspergillosis/Scedosporium & Fusarium infections, candidaemia in non-neutropenic patient Patient ≥40 kg 200 mg 12 hrly, <40 kg 100 mg 12 hrly. Co-administration w/ phenytoin If maintenance dose is increased from 200 mg to 400 mg 12 hrly. Patient <40 kg If maintenance dose is increased from 100 mg to 200 mg 12 hrly. Co-administration w/ adjusted doses of efavirenz Increase maintenance dose to 400 mg 12 hrly. IV Loading dose (1st 24 hr): 6 mg/kg 12 hrly. Maintenance dose (after 1st 24 hr): Prophylaxis of invasive fungal infections & candidaemia in non-neutropenic patient 3-4 mg/kg 12 hrly. Serious invasive Candida/invasive aspergillosis/Scedosporium & Fusarium infections 4 mg/kg 12 hrly. Co-administration w/ phenytoin If the maintenance dose is increased to 5 mg/kg 12 hrly. Adolescent (12-14 yr weighing <50 kg) & childn 2 to <12 yr Loading dose (1st 24 hr): Oral Not recommended. IV 9 mg/kg every 12 hr. Maintenance dose: Oral FC tab: 9 mg/kg bd. Max: 350 mg bd). Oral susp: 0.225 mL/kg (9 mg/kg) bd. Max: 8.75 mL (350 mg) bd. IV 8 mg/kg bd. Adolescent 12-14 yr, ≥50 kg; 15-16 yr regardless of body wt Adult dose. Prophylaxis in adult & childn Initiated on day of transplant for up to 100 days. Continuing immunosuppression or graft versus host disease May continue up to 180 days after transplant.

Should be taken on an empty stomach: FC tab: Take at least 1 hr before or after meals. Oral susp: Take at least 1 hr before or 2 hr after meals.

Hypersensitivity. Co-administration w/ CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide, quinidine or ivabradine; sirolimus; rifabutin, rifampicin, carbamazepine & long-acting barbiturates (eg, phenobarb); St. John's wort; efavirenz (≥400 mg once daily); ergot alkaloids (ergotamine, dihydroergotamine); high-dose ritonavir (≥400 mg bd); naloxegol; tolvaptan; venetoclax; lurasidone; finerenone.

Antifungals

J02AC03 - voriconazole ; Belongs to the class of triazole and tetrazole derivatives. Used in the systemic treatment of mycotic infections.

POM